Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP681192.RAB9YCqPIz0Y6v2Wm1RxpXX3X2sKwOk3EGId7uxqHDTvk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP681192.RAB9YCqPIz0Y6v2Wm1RxpXX3X2sKwOk3EGId7uxqHDTvk130_assertion type Assertion NP681192.RAB9YCqPIz0Y6v2Wm1RxpXX3X2sKwOk3EGId7uxqHDTvk130_head.
- NP681192.RAB9YCqPIz0Y6v2Wm1RxpXX3X2sKwOk3EGId7uxqHDTvk130_assertion description "[ABL KD mutations were detected by direct sequencing in 15 of 17 patients (88%) who had recurrent Ph-positive ALL and received prior imatinib (n = 16) or dasatinib (n = 1) treatment and in 6 of 7 patients (86%) who had resistant/recurrent tumors treated with >or=2 KIs compared with 0 of 12 patients with recurrent Ph-positive ALL who never received KIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP681192.RAB9YCqPIz0Y6v2Wm1RxpXX3X2sKwOk3EGId7uxqHDTvk130_provenance.
- NP681192.RAB9YCqPIz0Y6v2Wm1RxpXX3X2sKwOk3EGId7uxqHDTvk130_assertion evidence source_evidence_literature NP681192.RAB9YCqPIz0Y6v2Wm1RxpXX3X2sKwOk3EGId7uxqHDTvk130_provenance.
- NP681192.RAB9YCqPIz0Y6v2Wm1RxpXX3X2sKwOk3EGId7uxqHDTvk130_assertion SIO_000772 18615627 NP681192.RAB9YCqPIz0Y6v2Wm1RxpXX3X2sKwOk3EGId7uxqHDTvk130_provenance.
- NP681192.RAB9YCqPIz0Y6v2Wm1RxpXX3X2sKwOk3EGId7uxqHDTvk130_assertion wasDerivedFrom befree-2016 NP681192.RAB9YCqPIz0Y6v2Wm1RxpXX3X2sKwOk3EGId7uxqHDTvk130_provenance.
- NP681192.RAB9YCqPIz0Y6v2Wm1RxpXX3X2sKwOk3EGId7uxqHDTvk130_assertion wasGeneratedBy ECO_0000203 NP681192.RAB9YCqPIz0Y6v2Wm1RxpXX3X2sKwOk3EGId7uxqHDTvk130_provenance.